PDE5 Inhibitor Treatment Persistence and Adherence in Brazilian Men: Post-hoc Analyses from a 6-Month, Prospective, Observational Study

Abstract

ARTICLE INFO ______________________________________________________________ ______________________Purpose: Characterize persistence and adherence to phosphodiesterase type -5 inhibitor (PDE5I) on-demand therapy over 6 months among Brazilian men in an observational, non-interventional study of Latin American men naïve to PDE5Is with erectile dysfunction (ED). Materials and Methods:Men were prescribed PDE5Is per routine clinical practice. Persistence was defined as using ≥ 1 dose during the previous 4 -weeks, and adherence as following dosing instructions for the most recent dose, assessed using the Persistence and Adherence Questionnaire. Other measures included the Self -Esteem and Relationship (SEAR) Questionnaire, and International Index of Erectile Function (IIEF). Multivariate logistic regression was used to identify factors associated with persistence/adherence. Results: 104 Brazilian men were enrolled; mean age by treatment was 53 to 59 years, and most presented with moderate ED (61.7%). The prescribed PDE5I was sildenafil citrate for 50 (48.1%), tadalafil for 36 (34.6%), vardenafil for 15 (14.4%), and lodenafil for 3 patients (2.9%). Overall treatment persistence was 69.2% and adherence was 70.2%; both were numerically higher with tadalafil (75.0%) versus sildenafil or vardenafil (range 60.0% to 68.0%). Potential associations of persistence and/or adherence were observed with education level, ED etiology, employment status, and coronary artery disease. Improvements in all IIEF domain scores, and both SEAR domain scores were observed for all treatments. Study limitations included the observational design, brief duration, dependence on patient self -reporting, and limited sample size. Conclusion:Approximately two-thirds of PDE5I-naive, Brazilian men with ED were treatment persistent and adherent after 6 months. Further study is warranted to improve long-term outcomes of ED treatment.

The effect of tadalafil therapy on kidney damage caused by sepsis in a polymicrobial septic model induced in rats: a biochemical and histopathological study

“…Therefore, inhibition of PDE5 with tadalafil increases the level of both cGMP and nitric oxide in medium (6). PDE5 enzyme inhibition has been shown to increase local levels of cAMP and cGMP, which cause expansion in the vascular system (7).…”

Persistence Rate with Tadalafil for Treatment of Male Lower Urinary Tract Symptoms

“…There are no published data on persistence with tadalafil for treatment of male LUTS. A prospective observational study in Brazil indicated that persistence with PDE5 inhibitors in patients with erectile dysfunction (ED) was 69.2% at 6 months [7]. In this study, patients’ age was much younger (53–59 years old) than in the studies dealing with LUTS (e.g., mean age 71.9 years in the present study).…”

A comparison of the available phosphodie­sterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil

“…Another trial evaluated men in Central and South America using various PDE5Is. The trial 19 was a subset of data that focused on men in Brazil during a 6-month observational period researching which PDE5Is patients were more likely to be adherent with. The study allowed any available PDE5I to be used.…”